Why the study?
What are the safety, tolerability, and efficacy considerations for antiarrhythmic drugs in elderly patients with atrial fibrillation?
What are the safety, tolerability, and efficacy considerations for antiarrhythmic drugs in elderly patients with atrial fibrillation?
Careful evaluation and individualized treatment choices are necessary for elderly patients with atrial fibrillation due to complexities from age, comorbidities, and a lack of specific trial data.
Supports cautious antiarrhythmic selection in elderly AF now; leaves open need for dedicated age-specific trials.
With advancing age, atrial fibrillation is increasingly likely to indicate underlying cardiovascular disease and risk. An understanding of this is particularly important in the elderly patient, where likely triggers to atrial fibrillation and the influence of other pathologies on the safety and efficacy of proposed treatments will all contribute to optimal care of these patients. It is not yet clear whether rate control or cardioversion to sinus rhythm is the best strategy for the generality of patients with atrial fibrillation, and still less so for individuals. Age and comorbidity add complexities to this decision, which should inform the choice of drugs to be used. Further uncertainties arise from a literature that has often excluded elderly patients and derived its conclusions about mode of drug action from studies undertaken during sinus rhythm rather than atrial fibrillation. Despite these difficulties the careful evaluation of elderly patients with atrial fibrillation and their involvement in relevant choices should ensure optimum treatment for the individual.
No takes yet. Share an insight, caveat, or question.
Dayer et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: